Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-20

Clinical Trial Update: Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes? [Phase 2]

View source ↗

Summary

Phase 2 trial assessing whether doxazosin reduces stress-induced smoking and improves clinical outcomes, completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Doxazosin (doxazosin)

Snippet

Sponsor: Yale University | Conditions: Smoking | Phase 2 | Status: COMPLETED | Results posted: 2017-12-20